Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

December 23, 2024

June 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

June 01, 2024

TCTMD’s Top 10 Most Popular Stories for December 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

December 28, 2023

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

News Daily News

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

September 12, 2023

FDA Approves Colchicine for Decreasing CV Events

News Daily News

FDA Approves Colchicine for Decreasing CV Events

June 20, 2023

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

TCTMD’s Top 10 Most Popular Stories for March 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

April 02, 2021

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.